Patents by Inventor Kenjiro HIRA

Kenjiro HIRA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OPTICALLY ACTIVE AZABICYCLO RING DERIVATIVE
    Publication number: 20240148727
    Abstract: The compound of formula (1a) wherein p is 1 or 2, R1-R4 are hydrogen atom or the like, and a-d are 1 or 2, or a pharmaceutically acceptable salt thereof, which has an antitumor effect by inhibiting the binding between a MLL fusion protein that is infused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin.
    Type: Application
    Filed: January 12, 2024
    Publication date: May 9, 2024
    Applicant: Sumitomo Pharma Co., Ltd.
    Inventors: Seiji KAMIOKA, Hitoshi BAN, Naoaki SHIMADA, Wataru HIROSE, Akihiko ARAKAWA, Kazuto YAMAZAKI, Kenjiro HIRA
  • Optically active azabicyclo ring derivative
    Patent number: 11911381
    Abstract: The compound of formula (1a) wherein p is 1 or 2, R1-R4 are hydrogen atom or the like, and a-d are 1 or 2, or a pharmaceutically acceptable salt thereof, which has an antitumor effect by inhibiting the binding between a MLL fusion protein that is infused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin.
    Type: Grant
    Filed: May 23, 2022
    Date of Patent: February 27, 2024
    Assignee: Sumitomo Pharma Co., Ltd.
    Inventors: Seiji Kamioka, Hitoshi Ban, Naoaki Shimada, Wataru Hirose, Akihiko Arakawa, Kazuto Yamazaki, Kenjiro Hira
  • OPTICALLY ACTIVE AZABICYCLO RING DERIVATIVE
    Publication number: 20220288072
    Abstract: The compound of formula (1a) wherein p is 1 or 2, R1-R4 are hydrogen atom or the like, and a-d are 1 or 2, or a pharmaceutically acceptable salt thereof, which has an antitumor effect by inhibiting the binding between a MLL fusion protein that is infused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin.
    Type: Application
    Filed: May 23, 2022
    Publication date: September 15, 2022
    Applicant: Sumitomo Pharma Co., Ltd.
    Inventors: Seiji KAMIOKA, Hitoshi BAN, Naoaki SHIMADA, Wataru HIROSE, Akihiko ARAKAWA, Kazuto YAMAZAKI, Kenjiro HIRA
  • Optically active azabicyclo ring derivative
    Patent number: 11369605
    Abstract: The present invention relates to the compound of formula (1a) wherein p is 1 or 2, R1-R4 are hydrogen atom or the like, and a-d are 1 or 2, or a pharmaceutically acceptable salt thereof, which has an antitumor effect by inhibiting the binding between a MLL fusion protein that is infused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin.
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: June 28, 2022
    Assignee: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Seiji Kamioka, Hitoshi Ban, Naoaki Shimada, Wataru Hirose, Akihiko Arakawa, Kazuto Yamazaki, Kenjiro Hira
  • OPTICALLY ACTIVE AZABICYCLO RING DERIVATIVE
    Publication number: 20210338668
    Abstract: The present invention relates to the compound of formula (1a) wherein p is 1 or 2, R1-R4 are hydrogen atom or the like, and a-d are 1 or 2, or a pharmaceutically acceptable salt thereof, which has an antitumor effect by inhibiting the binding between a MLL fusion protein that is infused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin.
    Type: Application
    Filed: August 26, 2019
    Publication date: November 4, 2021
    Applicant: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Seiji KAMIOKA, Hitoshi BAN, Naoaki SHIMADA, Wataru HIROSE, Akihiko ARAKAWA, Kazuto YAMAZAKI, Kenjiro HIRA
  • Optically active azabicyclo ring derivative
    Patent number: 10815241
    Abstract: The present invention relates to the compound of formula (1a) wherein p is 1 or 2, R1-R4 are hydrogen atom or the like, and a-d are 1 or 2, or a pharmaceutically acceptable salt thereof, which has an antitumor effect by inhibiting the binding between a MLL fusion protein that is infused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin.
    Type: Grant
    Filed: January 21, 2020
    Date of Patent: October 27, 2020
    Assignee: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Seiji Kamioka, Hitoshi Ban, Naoaki Shimada, Wataru Hirose, Akihiko Arakawa, Kazuto Yamazaki, Kenjiro Hira
  • OPTICALLY ACTIVE AZABICYCLO RING DERIVATIVE
    Publication number: 20200157114
    Abstract: The present invention relates to the compound of formula (1a) wherein p is 1 or 2, R1-R4 are hydrogen atom or the like, and a-d are 1 or 2, or a pharmaceutically acceptable salt thereof, which has an antitumor effect by inhibiting the binding between a MLL fusion protein that is infused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin.
    Type: Application
    Filed: January 21, 2020
    Publication date: May 21, 2020
    Applicant: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Seiji KAMIOKA, Hitoshi BAN, Naoaki SHIMADA, Wataru HIROSE, Akihiko ARAKAWA, Kazuto YAMAZAKI, Kenjiro HIRA
  • SALTS OF A HETEROCYCLIC COMPOUND AND CRYSTALLINE FORMS, PROCESSES FOR PREPARING, THERAPEUTIC USES, AND PHARMACEUTICAL COMPOSITIONS THEREOF
    Publication number: 20190375764
    Abstract: The present disclosure relates to salts of (R)-1-(3,4-dihydro-1H-[1,4]oxazino[4,3-b]indazol-1-yl)-N-methylmethanamine, crystalline forms thereof, and methods of preparation thereof, which are useful in the treatment of CNS disorders.
    Type: Application
    Filed: June 6, 2019
    Publication date: December 12, 2019
    Inventors: Nandkumar Nivritti BHOGLE, Yuji FUJIWARA, Kenjiro HIRA, Tomoya KARASAWA, Kostas SARANTEAS, John R. SNOONIAN, Harold Scott WILKINSON, Haitao ZHANG